Summary

CLM-104 is a CAR-T cell therapy indicated for various solid tumors including triple-negative breast cancer. With binding to CellabMED’s own solid tumors with various targets being confirmed, additional indications are expected to other solid tumors including triple-negative breast cancer with this treatment modality.

Structure and mechanism of action

It is a Chimeric antigen receptor T cell (CAR-T), cell and gene therapy that targets and eliminates cancer cells in triple-negative breast cancer.

Technical advantage

- CLM-104 targets cancer-specific antigens found in a variety of solid tumors, including triple-negative breast cancer.

- CLM-104 is an scFv-based CAR-T that can recognize both isoforms of the target antigen, opening new indications for this treatment.